| Lauren C Aberegg, MD | |
|
55 Merz Blvd Unit A, Fairlawn, OH 44333-2895 | |
| (330) 864-9000 | |
| (330) 864-9004 |
| Full Name | Lauren C Aberegg |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 7 Years |
| Location | 55 Merz Blvd Unit A, Fairlawn, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477083111 | NPI | - | NPPES |
| 0454301 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 35.141509 (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fairlawn Dermatology Llc | 4789616806 | 5 |
News Archive
Enthusiasm for an emerging digital health tool, the smart pill, is on the rise but researchers at the University of Illinois at Chicago have published a paper in the American Journal of Bioethics that cautions health care providers and policymakers to slow down when it comes to allowing this technology in patient care settings.
DexCom, Inc. today reported its audited financial results as of and for the quarter and fiscal year ended December 31, 2013.
Treatment with creatine monohydrate for at least 5 years for patients with early and treated Parkinson disease failed to slow clinical progression of the disease, compared with placebo, according to a study in the February 10 issue of JAMA.
The New York Times explores how congressional staffs are anxious about a health law provision requiring them to buy coverage in online insurance markets because the federal government may no longer pay a share of their premiums.
Shire plc, the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for velaglucerase alfa, the company's enzyme replacement therapy (ERT) in development for the treatment of Type 1 Gaucher disease, will be presented at the Lysosomal Disease Network (LDN) World Symposium, February 10-12, 2010 in Miami, Florida.
› Verified 8 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
Enthusiasm for an emerging digital health tool, the smart pill, is on the rise but researchers at the University of Illinois at Chicago have published a paper in the American Journal of Bioethics that cautions health care providers and policymakers to slow down when it comes to allowing this technology in patient care settings.
DexCom, Inc. today reported its audited financial results as of and for the quarter and fiscal year ended December 31, 2013.
Treatment with creatine monohydrate for at least 5 years for patients with early and treated Parkinson disease failed to slow clinical progression of the disease, compared with placebo, according to a study in the February 10 issue of JAMA.
The New York Times explores how congressional staffs are anxious about a health law provision requiring them to buy coverage in online insurance markets because the federal government may no longer pay a share of their premiums.
Shire plc, the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for velaglucerase alfa, the company's enzyme replacement therapy (ERT) in development for the treatment of Type 1 Gaucher disease, will be presented at the Lysosomal Disease Network (LDN) World Symposium, February 10-12, 2010 in Miami, Florida.
› Verified 8 days ago
| Entity Name | Fairlawn Dermatology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356376917 PECOS PAC ID: 4789616806 Enrollment ID: O20060919000127 |
News Archive
Enthusiasm for an emerging digital health tool, the smart pill, is on the rise but researchers at the University of Illinois at Chicago have published a paper in the American Journal of Bioethics that cautions health care providers and policymakers to slow down when it comes to allowing this technology in patient care settings.
DexCom, Inc. today reported its audited financial results as of and for the quarter and fiscal year ended December 31, 2013.
Treatment with creatine monohydrate for at least 5 years for patients with early and treated Parkinson disease failed to slow clinical progression of the disease, compared with placebo, according to a study in the February 10 issue of JAMA.
The New York Times explores how congressional staffs are anxious about a health law provision requiring them to buy coverage in online insurance markets because the federal government may no longer pay a share of their premiums.
Shire plc, the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for velaglucerase alfa, the company's enzyme replacement therapy (ERT) in development for the treatment of Type 1 Gaucher disease, will be presented at the Lysosomal Disease Network (LDN) World Symposium, February 10-12, 2010 in Miami, Florida.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lauren C Aberegg, MD 55 Merz Blvd Unit A, Fairlawn, OH 44333-2895 Ph: (330) 864-9000 | Lauren C Aberegg, MD 55 Merz Blvd Unit A, Fairlawn, OH 44333-2895 Ph: (330) 864-9000 |
News Archive
Enthusiasm for an emerging digital health tool, the smart pill, is on the rise but researchers at the University of Illinois at Chicago have published a paper in the American Journal of Bioethics that cautions health care providers and policymakers to slow down when it comes to allowing this technology in patient care settings.
DexCom, Inc. today reported its audited financial results as of and for the quarter and fiscal year ended December 31, 2013.
Treatment with creatine monohydrate for at least 5 years for patients with early and treated Parkinson disease failed to slow clinical progression of the disease, compared with placebo, according to a study in the February 10 issue of JAMA.
The New York Times explores how congressional staffs are anxious about a health law provision requiring them to buy coverage in online insurance markets because the federal government may no longer pay a share of their premiums.
Shire plc, the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for velaglucerase alfa, the company's enzyme replacement therapy (ERT) in development for the treatment of Type 1 Gaucher disease, will be presented at the Lysosomal Disease Network (LDN) World Symposium, February 10-12, 2010 in Miami, Florida.
› Verified 8 days ago
Dr. Kimberly Tamargo, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3624 W Market St Ste 101, Fairlawn, OH 44333 Phone: 330-665-0555 | |
Ann R Kooken, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3624 W Market St Ste 101, Fairlawn, OH 44333 Phone: 330-665-0555 Fax: 330-665-0556 | |
Dr. Allison J Moosally, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3624 W Market St, Suite 101, Fairlawn, OH 44333 Phone: 330-665-0555 Fax: 330-665-0556 | |
Dr. Gary D Lichten, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 3624 W Market St, Fairlawn, OH 44333 Phone: 330-665-0555 Fax: 330-665-0556 | |
James F Libecco, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3624 W Market St, Fairlawn, OH 44333 Phone: 330-665-0555 Fax: 330-665-0556 | |
Valerie W. Fuller, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 55 Merz Blvd., Ste A, Fairlawn, OH 44333 Phone: 330-864-9000 Fax: 330-864-9004 |